Stromal disrupting effects of nab-paclitaxel in pancreatic cancer

BACKGROUND: Nab-paclitaxel and gemcitabine have demonstrated a survival benefit over gemcitabine alone in advanced pancreatic cancer (PDA). This study aimed to investigate the clinical, biological, and imaging effects of the regimen in patients with operable PDA. METHODS: Patients with operable PDA...

Descripción completa

Detalles Bibliográficos
Autores principales: Alvarez, R, Musteanu, M, Garcia-Garcia, E, Lopez-Casas, P P, Megias, D, Guerra, C, Muñoz, M, Quijano, Y, Cubillo, A, Rodriguez-Pascual, J, Plaza, C, de Vicente, E, Prados, S, Tabernero, S, Barbacid, M, Lopez-Rios, F, Hidalgo, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749580/
https://www.ncbi.nlm.nih.gov/pubmed/23907428
http://dx.doi.org/10.1038/bjc.2013.415

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749580/
https://www.ncbi.nlm.nih.gov/pubmed/23907428
http://dx.doi.org/10.1038/bjc.2013.415

Ejemplares similares